GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Pfizer completes acquisition of Global Blood Therapeutics
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
- Details
- Category: Eli Lilly and Company
![Eli Lilly and Company Eli Lilly and Company](/images/logo/lilly.png)
Pfizer completes acquisition of Biohaven Pharmaceuticals
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
More Pharma News ...
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Novartis invests in early technical development capabilities for next-generation biotherapeutics
- FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
- Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
- BioNTech's statement on patent infringement lawsuit filed by Moderna
- Moderna sues Pfizer and BioNTech for infringing patents central to Modernas innovative mRNA technology platform
- Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off